Gilde Healthcare Partners awarded European Venture Fundraising of the year - Gilde Healthcare

Gilde Healthcare Partners awarded European Venture Fundraising of the year

12 februari 2008

Utrecht – Gilde Healthcare Partners, a rapidly growing European venture capital firm, has received the Venture Fundraising of the Year Award from the European Venture Capital Journal. The Award was for the successful closing of Gilde Healthcare II (GHC II), its EUR 150 million venture fund, in 2007. The original target for GHC II was EUR 125 million.

GHC II is one of the largest venture funds raised to invest in European healthcare opportunities. GHC II was backed by current investors in Gilde Healthcare Funds, who were joined by a small select group of new investors. Investors were attracted by Gilde Healthcare Partners’ excellent investment track record which has seen it achieve six successful exits in the past two years.
 
Gilde Healthcare Partners invests in strong professional management teams developing therapeutics, diagnostics, medical devices and enabling technologies. Gilde creates significant value for both its investors and the driven entrepreneurs it backs by selectively investing in companies with well thought-out business models. The fund invests at all stages of a company’s development from seed stage to pre-IPO rounds. Gilde’s investments range from EUR 1 million up to EUR 15 million per investee company after all private rounds of financing. 
Founded in 2000, Gilde Healthcare Partners is headquartered in Utrecht, The Netherlands with representatives in London and Madrid. Gilde Healthcare Partners currently has over EUR 275 million (USD 400 million) under management. Gilde is an ambitious builder of healthcare businesses across Europe. Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include Ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France), Santaris Pharma (Denmark) and Symphogen (Denmark). For a full list of Gilde’s portfolio companies please visit the website.

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international growth in the medical imaging market

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in...
16 december 2024

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first...
12 december 2024

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital...
11 december 2024